TEDxTalks: The surprising story of medical Cannabis and pediatric epilepsy: Josh Stanley at TEDxBoulder 2013

TEDxTalks

The surprising story of medical Cannabis and pediatric epilepsy: Josh Stanley at TEDxBoulder 2013

Published on Oct 14, 2013

Josh will sift through the propaganda, fear and greed encompassing medical marijuana. Recently featured on CNN, Josh and his brothers developed a non-psychotropic strain of marijuana which is drastically reducing seizures for many pediatric epilepsy patients in Colorado. With millions facing life-threatening illnesses, Josh outlines the hurdles needed to effect social change and maps a path toward helping those who desperately need revolutionary medicine.

sep-bar-4

Advertisements

Study shows non-hallucinogenic cannabinoids are effective anti-cancer drugs

medical-marijuanaNew research has shown that the non-hallucinogenic components of cannabis could act as effective anti-cancer agents.

The anti-cancer properties of tetrahydrocannabinol (THC), the primary hallucinogenic component of cannabis, has been recognised for many years, but research into similar cannabis-derived compounds, known as cannabinoids, has been limited.

The study was carried out by a team at St George’s, University of London. It has been published in the journal Anticancer Research.

The team, led by Dr Wai Liu and colleagues carried out laboratory investigations using a number of cannabinoids, either alone or in combination with each other, to measure their anti-cancer actions in relation to leukaemia.

Of six cannabinoids studied, each demonstrated anti-cancer properties as effective as those seen in THC. Importantly, they had an increased effect on cancer cells when combined with each other.

Dr Liu said: “This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising.

“These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own.

“Used in combination with existing treatment, we could discover some highly effective strategies for tackling cancer. Significantly, these compounds are inexpensive to produce and making better use of their unique properties could result in much more cost effective anti-cancer drugs in future.”

This latest research is part of a growing portfolio of studies into the medicinal properties of cannabis by the research team at St George’s. The next step will be to examine in the laboratory these compounds in combination with existing anti-cancer treatments and study treatment schedules to identify strategies that will maximise their efficacy.

The study examined two forms of cannabidiol (CBD), two forms of cannabigerol (CBG) and two forms of cannabigevarin (CBGV). These represent the most common cannabinoids found in the cannabis plant apart from THC.

Ends

Notes to Editors

For more information or interviews, contact St George’s, University of London Communications on 0208 725 1139 or at media@sgul.ac.uk.

Cannabis, also known as marijuana, is a plant from Central Asia that is grown in many parts of the world today. It is a controlled substance in the UK and is most commonly known as a recreational drug.

Cannabinoids are active chemicals in cannabis. They are also known more specifically as phytocannabinoids. There are 85 known cannabinoids in the cannabis plant. The main active cannabinoid in Cannabis is delta-9-tetrahydrocannabinol (THC).

The cannabis plant is known for its medicinal properties and has been used to relieve symptoms associated with cancer, HIV/AIDS, multiple sclerosis, anorexia, anxiety, depression, and numerous other illnesses and conditions.

Read the full research paper in the journal Anticancer Researchhttp://ar.iiarjournals.org/content/33/10/4373.abstract

readbutton.pnghttp://www.sgul.ac.uk/media/latest-news/study-shows-non-hallucinogenic-cannabinoids-are-effective-anti-cancer-drugs

Modesto dad turns to medical marijuana to save son diagnosed with Dravet’s Syndrome

jason.jadonMODESTO, Calif. (KCRA) —Jason David from Modesto chronicles the ups and downs with his 6-year-old son Jayden, who was diagnosed with Dravet syndrome, on a Facebook page called Jason and Jayden’s Journey.

Jayden was diagnosed with Dravet, a rare form of epilepsy, when he was a baby. Since then, he has had seizures preventing him from walking, playing and living life.

“At one point Jayden had seizures 24 hours a day lasting an hour and a half,” David said. “I went to my doctor and said, ‘I don’t think Jayden is going to last, he can’t sleep, can’t eat, he hasn’t used the restroom, he can’t do anything.'”

David said his son has been taken away in an ambulance more than 40 times. He’s also taken 22 pills a day — 12 different kinds and none of them worked.

David said it got so bad that he wanted to kill himself and put a gun to his head.

But now, those thoughts are long gone.

As a last resort, David turned to medical marijuana. Specifically, a liquid form that contains a component known as CBD.

Jayden’s pediatrician prescribes it to Jayden and says the liquid form maintains medicinal qualities, while giving less of a high.

Jayden has been getting a few drops a day for the past two years and David said it’s been a remarkable difference.

Jayden is the most independent he’s ever been. He plays well, can walk and give his dad high fives, David said.

“(The) first day I gave him medical marijuana, thank God. (It was) the first day he went seizure free in his life,”he said.David said he wants to share his story to help other parents in the same situation.

He says parents need to educate themselves and do what’s right for their own children.

The father and son have been featured in numerous articles and television shows. Jason and Jayden will be featured as a small piece in a special about medical marijuana with Dr. Sanjay Gupta that airs Sunday on CNN.

Jayden’s pediatrician said he is seeing more children with autism and seizures who are benefiting from medical marijuana.

The doctor admits not a lot of studies have been done on medicinal marijuana, which is why doctors across the board may have differing opinions.

However, doctors at the University of California-San Francisco are now studying the affects the CBD component in medical marijuana has on epileptic children.

readbutton.pngRead more: http://www.kcra.com/news/local-news/news-modesto/modesto-dad-turns-to-medical-marijuana-to-save-son/-/12970436/21394696/-/frdj10/-/index.html#ixzz2fjai3tyH

Cured Too: A Cancer Story: A Film By David Triplett

Cured Too: A Cancer Story: A Film By David Triplett

This is a documentary of how myself and others cured our cancers using an alternative and controversial treatment: cannabis oil. It’s a proven fact that CBD and THC, two of many components in cannabis, shrink tumors and cure cancer. This documentary shows my cancer being cured and explores the history and politics of cannabis and cancer. You will also see samples of many antique cannabis medicine bottles.

Active Ingredient in Cannabis Kills Cancer Cells in Brain

LabNew research out of Spain suggests that THC — the active ingredient in marijuana — appears to prompt the death of brain cancer cells.

The finding is based on work with mice designed to carry human cancer tumors, as well as from an analysis of THC’s impact on tumor cells extracted from two patients coping with a highly aggressive form of brain cancer.

Explaining that the introduction of THC into the brain triggers a cellular self-digestion process known as “autophagy,” study co-author Guillermo Velasco said his team has isolated the specific pathway by which this process unfolds, and noted that it appears “to kill cancer cells, while it does not affect normal cells.”

Velasco is with the department of biochemistry and molecular biology in the School of Biology at Complutense University in Madrid. The findings were published in the April issue of The Journal of Clinical Investigation.

The Spanish researchers focused on two patients suffering from “recurrent glioblastoma multiforme,” a fast-moving form of brain cancer. Both patients had been enrolled in a clinical trial designed to test THC’s potential as a cancer therapy.

Using electron microscopes to analyze brain tissue taken both before and after a 26- to 30-day THC treatment regimen, the researchers found that THC eliminated cancer cells while it left healthy cells intact.

The team also was able, in what it described as a “novel” discovery, to track the signaling route by which this process was activated.

These findings were replicated in work with mice, which had been “engineered” to carry three different types of human cancer tumor grafts.

“These results may help to design new cancer therapies based on the use of medicines containing the active principle of marijuana and/or in the activation of autophagy,” Velasco said.

Outside experts suggested that more research is needed before advocating marijuana as a medicinal intervention for brain cancer.

Dr. John S. Yu, co-director of the Comprehensive Brain Tumor Program in the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center in Los Angeles, said the findings were “not surprising.”

“There have been previous reports to this effect as well,” he said. “So this is yet another indication that THC has an anti-cancer effect, which means it’s certainly worth further study. But it does not suggest that one should jump at marijuana for a potential cure for cancer, and one should not urge anyone to start smoking pot right away as a means of curing their own cancer.”

But that’s exactly what many brain cancer patients have been doing, said Dr. Paul Graham Fisher, the Beirne Family director of Neuro-Oncology at Stanford University.

“In fact, 40 percent of brain tumor patients in the U.S. are already using alternative treatments, ranging from herbals to vitamins to marijuana,” he said. “But that actually points out a cautionary tale here, which is that many brain cancer patients are already rolling a joint to treat themselves, but we’re not really seeing brain tumors suddenly going away as a result, which we clearly would’ve noticed if it had that effect. So we need to be open-minded. But this suggests that the promise of THC might be a little over-hoped, and certainly requires further investigation before telling people to go out and roll a joint.”

By Alan Mozes

HealthDay Reporter
April 2

More information

For additional details on the risks and benefits of marijuana use as it relates to cancer, visit the National Cancer Institute or the American Cancer Society.

SOURCES: Guillermo Velasco, Ph.D., department of biochemistry and molecular biology, School of Biology, Complutense University, Madrid; John S. Yu, M.D., co-director, Comprehensive Brain Tumor Program, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles; Paul Graham Fisher, M.D., associate professor, neurology, pediatrics, and neurosurgery and human biology and the Beirne Family Director of Neuro-Oncology, Stanford University; April 2009, The Journal of Clinical Investigation

readbutton.png

Cannabidiol (CBD) “Turns Off” the Cancer Gene Involved in Metastasis Findings by Scientists at California Pacific Medical Center gives Scientific Support for Cannabis Science Initiatives

products_overviewNew studies by Scientists at California Pacific Medical Center, have shown that cannabidiol, (CBD), has the ability to “turn off” a gene that causes breast and other types of cancers to metastasize, according to the San Francisco Chronicle newspaper.

NBC News reports, “The drug “has been shown to reduce pain and nausea” in cancer patients. AIDS patients also use cannabis to eat, sleep and otherwise be more functional. Turns out that cannabidiol has none of the psychotropic effects of marijuana as a whole. The researchers hope to move to clinical trials on humans soon to test the cannabidiol inhibition of metastasis, reported in the San Francisco Chronicle. “What they found is that the cannabinoid turns off the overexpression of ID-1, which makes the cells lose their ability to travel to distant tissues. In other words, it keeps the cells more local and blocks their ability to metastasize. (spread to a new location) The researchers stressed cannabidiol works only on cancer cells that have these high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. But they’ve found such high levels in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers.”

Cannabis Science appreciates this additional scientific support that this report provides for our two target drug development programs as the Company moves forward with CS-TATI-1, and based on the success of previous skin cancer patients who self-administered cannabis-based treatments, the Company is focusing on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Dr. Robert Melamede states, “Cannabis Science is excited for the increasing scientific support for our projects. In the near future, we will share new developments, as well a the progress we have made with our earlier defined initiatives. Our professional expansion and development, as detailed in our latest news releases,was driven by the science of how cannabinoids can benefit both HIV/AIDS and Cancer Patients.”

San Francisco Chronicle: http://www.sfgate.com/health/article/Pot-compound-seen-as-tool-against-cancer-3875562.php#page-1

About CS-S/BCC-1

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Cannabis Science has already seen success with 4 self-medicated skin cancer patients. These patients have been self-administering using cannabis-based extracts applied topically to their carcinomas and tumors. These patients have experienced shrinking and apparent eradication of their skin cancer, backed by positive reports from their doctors, which is why the Company is confident about the eminent success of this new drug to be developed.

About CS-TATI-1

Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

readbutton.png

Cannabis Compound (CBD) May Beat Antipsychotics at Treating Schizophrenia

By  Associate News Editor

Reviewed by John M. Grohol, Psy.D. on June 7, 2012

arizona-medical-marijuana-testing-cbd

A certain marijuana compound known as cannabidiol (CBD) can treat schizophrenia as well as antipsychoticdrugs, with far fewer side effects, according to a preliminary clinical trial.

The research team, led by Markus Leweke of the University of Cologne in Germany, studied 39 people with schizophrenia who were hospitalized for a psychotic episode. Nineteen patients were treated with amisulpride, an antipsychotic medication that is not approved in the U.S., but is similar to other approved drugs.

The remaining 20 patients were given CBD, a substance found in marijuana that is considered responsible for the mellowing or anxiety-reducing effects. Unlike the main ingredient in marijuana, THC, which can trigger psychotic episodes and worsen schizophrenia, CBD has antipsychotic effects, according to prior research in both animals and humans.

Neither the patients nor the scientists knew who was receiving which drug. At the end of the four-week trial, both groups made significant clinical improvements in their schizophrenic symptoms, and there was no difference between those getting CBD or amisulpride.

“The results were amazing,” said Daniel Piomelli, Ph.D., professor of pharmacology at the University of California-Irvine and a co-author of the study. “Not only was [CBD] as effective as standard antipsychotics, but it was also essentially free of the typical side effects seen with antipsychotic drugs.”

Antipsychotic drugs may cause devastating and sometimes permanent movement disorders; they can also lower a patient’s motivation and pleasure. The new generation of these drugs can also lead to weight gain and increase the risk for diabetes. These side effects are well known as a major hindrance during treatment.

In the German study, weight gain and movement problems were observed in patients taking amisulpride, but not CBD.

“These exciting findings should stimulate a great deal of research,” said Dr. John Krystal, chair of psychiatry at Yale University School of Medicine, who was not associated with the research. He notes that CBD not only had fewer side effects, but also seemed to work better on schizophrenia’s so-called “negative symptoms,” which are notoriously hard to treat.

Negative symptoms of schizophrenia include social withdrawal, a lowered sense of pleasure and a lack of motivation. However, since current antipsychotic medications can actually cause these negative symptoms, it wasn’t clear whether CBD was better than amisulpride at getting rid of these symptoms, or whether CBD simply caused fewer side effects to begin with.

If replicated, the results suggest that CBD may be at least as effective as current medications for the treatment of schizophrenia, without the severe side effects that make patients reluctant to take medication.

“The real problem with CBD is that it’s hard to develop for a variety of silly reasons,” said Piomelli. Since it comes from marijuana, there are obvious political issues surrounding its use. Extracting it from the plant is also expensive.

But the biggest obstacle may be that CBD is a natural compound, and therefore can’t be patented the way new drugs are. So although CBD could outsell the current blockbuster antipsychotic drugs, pharmaceutical companies aren’t likely to develop it. Researchers are working to develop synthetic versions of CBD that would avoid such hurdles.

“We have one and are hoping to move forward in the near future,” Piomelli said.

The study is published online in the journal Translational Psychiatry.

Source:  University of Cologne

readbutton.png